Seres Therapeutics
MCRB
82 hedge funds and large institutions have $232M invested in Seres Therapeutics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 30 increasing their positions, 14 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
114% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 14
62% more capital invested
Capital invested by funds: $143M → $232M (+$88.9M)
17% more funds holding
Funds holding: 70 → 82 (+12)
0.23% more ownership
Funds ownership: 3.88% → 4.11% (+0.23%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
57% less call options, than puts
Call options by funds: $102K | Put options by funds: $237K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$7.12M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$4.97M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$4.88M |
| 4 |
Millennium Management
New York
|
+$1.78M |
| 5 |
JP Morgan Chase
New York
|
+$1.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$10.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.87M |
| 3 |
BlackRock
New York
|
-$343K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$196K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$174K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
76
Tower Research Capital (TRC)
New York
| $2K | -$88.5K | -726 | -98% |
|
77
Daiwa Securities Group
Tokyo,
Japan
| $2K | – | – | – |
|
|
PCA
78
Peddock Capital Advisors
Braintree,
Massachusetts
| $2K | – | – | – |
|
|
HR
79
Howe & Rusling
Rochester,
New York
| $1K | – | – | – |
|
|
MCM
80
Manchester Capital Management
Manchester,
Vermont
| $1K | – | – | – |
|
|
81
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$196K | -1,608 | Closed |
|
82
Tudor Investment Corp
Stamford,
Connecticut
| – | -$54K | -595 | Closed |
|
83
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | -14 | Closed |
|
MCRB Hedge Fund Activity: Q1 2019 in Review
82 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q1 2019, worth a combined $232M — up 62% from $143M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new MCRB positions and 4 closed out — a net gain of 12 holders — while 30 added to existing stakes and 14 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $7.12M. The largest seller was Federated Hermes, cutting an estimated $10.6M.
- 82 institutional investors held Seres Therapeutics (MCRB) as of Q1 2019, up from 70 in Q4 2018.
- Funds reported $232M of Seres Therapeutics stock for Q1 2019, up 62% quarter-over-quarter.
- 16 funds opened new Seres Therapeutics positions in Q1 2019 and 4 closed out, a net change of +12 holders.
- The largest Seres Therapeutics buyer in Q1 2019 was ARK Investment Management, an estimated $7.12M added.
- The largest Seres Therapeutics seller in Q1 2019 was Federated Hermes, an estimated $10.6M sold.
Based on aggregated 13F filings for Q1 2019.